Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 2
1966 2
1967 8
1968 4
1969 5
1970 4
1971 5
1972 5
1973 6
1974 9
1975 14
1976 25
1977 14
1978 20
1979 18
1980 17
1981 20
1982 15
1983 13
1984 19
1985 15
1986 16
1987 25
1988 16
1989 22
1990 21
1991 22
1992 15
1993 16
1994 11
1995 27
1996 28
1997 30
1998 21
1999 15
2000 23
2001 23
2002 24
2003 20
2004 34
2005 24
2006 33
2007 34
2008 30
2009 30
2010 43
2011 33
2012 33
2013 41
2014 31
2015 39
2016 37
2017 37
2018 39
2019 51
2020 97
2021 115
2022 134
2023 123
2024 108
2025 74
2026 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,713 results

Results by year

Filters applied: . Clear all
Page 1
Glycan-Binding Proteins in Immunity.
Rabinovich GA, Rademacher C, Schattner M, Macauley MS. Rabinovich GA, et al. Annu Rev Immunol. 2026 Feb 24. doi: 10.1146/annurev-immunol-083024-030822. Online ahead of print. Annu Rev Immunol. 2026. PMID: 41729700 Review.
Glycan-binding proteins (GBPs), including Galectins, sialic acid-binding immunoglobin-type lectins (Siglecs), and C-type lectin receptors (CLRs), are key regulators of immune cell development, activation, differentiation, trafficking, and homeostasis. ...
Glycan-binding proteins (GBPs), including Galectins, sialic acid-binding immunoglobin-type lectins (Siglecs), and C-type lectin recep …
Omalizumab.
[No authors listed] [No authors listed] 2026 Feb 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2026 Feb 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000860 Free Books & Documents. Review.
Recurrent Miller Fisher Syndrome: A Case Report.
Vernier L, Gilmore GB, Van Housen K, Zhang XC. Vernier L, et al. Clin Pract Cases Emerg Med. 2026 Feb;10(1):97-100. doi: 10.5811/cpcem.47931. Clin Pract Cases Emerg Med. 2026. PMID: 41666885 Free PMC article.
INTRODUCTION: Guillain-Barre syndrome can manifest with progressive paralysis, requiring careful monitoring and treatment with steroids or intravenous (IV) immunoglobin. While this disease can be devastating and require intensive care unit level of care, there are few inci …
INTRODUCTION: Guillain-Barre syndrome can manifest with progressive paralysis, requiring careful monitoring and treatment with steroids or i …
Beneficial Effects of Intravenous Immunoglobulin Treatment in a Mouse Preclinical Model of Severe Traumatic Brain Injury.
Chen M, Puhakka N, Edson J, Cui X, Lai A, Romero KS, Gallo CS, Migotto MA, Edwards S, Peshtenski E, Pitkänen A, Reutens D. Chen M, et al. J Neurotrauma. 2025 Dec 18. doi: 10.1177/08977151251401566. Online ahead of print. J Neurotrauma. 2025. PMID: 41467983
The present study evaluated the therapeutic effects of intravenous immunoglobin (IVIg), a well-established immunomodulatory treatment, in a controlled cortical impact model of severe TBI in mice. ...
The present study evaluated the therapeutic effects of intravenous immunoglobin (IVIg), a well-established immunomodulatory treatment …
Identification and Characterization of Platelet Surface-membrane-derived Microparticles before and after Total-body Irradiation.
Nounamo B, Cholia RP, Dub R, Larrey EK, Pineda EN, Porterc R, Ware J, Pathak R. Nounamo B, et al. Radiat Res. 2025 Dec 12. doi: 10.1667/RADE-25-00165.1. Online ahead of print. Radiat Res. 2025. PMID: 41421387
Depending on sex, mouse strain, and TBI status, total microparticle count and microparticles-mediated ROS generation and immunoglobin production were altered in RAW264.7 cells and splenic B cells, respectively. ...
Depending on sex, mouse strain, and TBI status, total microparticle count and microparticles-mediated ROS generation and immunoglobin …
Maternal Immunoglobulin Treatment of Gestational Alloimmune Liver Disease to Prevent Neonatal Liver Failure: A Single Center Case Series.
Gabrysch CH, Dressler-Steinbach I, Verlohren S, Bührer C, Mayer B, Dame C. Gabrysch CH, et al. Transfus Med Hemother. 2025 Sep 18;52(6):368-378. doi: 10.1159/000548476. eCollection 2025 Dec. Transfus Med Hemother. 2025. PMID: 41368233 Free PMC article.
Understanding the immunological origin resulted in the concept of treatment with high-dose intravenous immunoglobins (IVIG) during gestation. METHODS: This retrospective single-center cohort study consists of seven women with index cases of GALD, followed by a total of ten …
Understanding the immunological origin resulted in the concept of treatment with high-dose intravenous immunoglobins (IVIG) during ge …
IgG binding characteristics of ferret Fcγ receptors.
Ge X, Stoner M, Weiner JA, Balderas Hernández ME, Taher N, Khanwalkar US, Carpenter MC, Lee J, Ackerman ME. Ge X, et al. MAbs. 2025 Dec;17(1):2590248. doi: 10.1080/19420862.2025.2590248. Epub 2025 Nov 17. MAbs. 2025. PMID: 41250609 Free PMC article.
A Case Report of Using Intravitreal Dexamethasone Implants as the Bridging Treatment for Ocular Manifestations in Susac Syndrome.
Tran EM, Huang L. Tran EM, et al. Ocul Immunol Inflamm. 2025 Nov;33(9):2209-2212. doi: 10.1080/09273948.2025.2553217. Epub 2025 Aug 26. Ocul Immunol Inflamm. 2025. PMID: 41182823 Review.
After ocular treatments, systemic therapies were modified with the addition of monthly intravenous immunoglobin infusion. CONCLUSION: In cases of delayed systemic immunosuppressive therapies, intravitreal dexamethasone can be considered as a bridging treatment for ocular m …
After ocular treatments, systemic therapies were modified with the addition of monthly intravenous immunoglobin infusion. CONCLUSION: …
1,713 results